[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365047-105":59,"doc-detail-365047-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-characterization-and-therapeutic-targeting-of-fusion-genes-in-oncology","Clinical characterization and therapeutic targeting of fusion genes in oncology","","Gene fusions are oncogenic driver mutations that create aberrant cellular signaling and can be detected in up to 17% of solid tumors. Precision therapies that target fusion gene signaling have shown clinical benefit, and next-generation sequencing plus bioinformatics have expanded treatment options across patient subpopulations. Tyrosine inhibitors can be effective for fusion gene–expressing cancers. Fusion genes are also clonal mutations, representing a personal tumor target across all cancer cells. The review covers fusion gene targeting, mechanisms of therapeutic resistance, and relevant molecular biomarkers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-characterization-and-therapeutic-targeting-of-fusion-genes-in-oncology/365047/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-characterization-and-therapeutic-targeting-of-fusion-genes-in-oncology/365047.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are fusion genes and why are they important in oncology?","Question",{"text":112,"@type":113},"Fusion genes are oncogenic driver mutations that produce aberrant cellular signaling. They can be identified in a substantial fraction of solid tumors and contribute to cancer development and progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How have next-generation sequencing and bioinformatics expanded fusion-gene therapies?",{"text":117,"@type":113},"Advances in clinically relevant next-generation sequencing and bioinformatic analyses enable detection of fusion gene expression and broaden therapeutic opportunities for different patient subpopulations.",{"name":119,"@type":110,"acceptedAnswer":120},"Why are fusion genes considered clonal mutations and how does that affect treatment?",{"text":121,"@type":113},"Fusion genes are clonal mutations, serving as a personal cancer target across essentially all cancer cells in a patient’s tumor mass. This supports therapeutic strategies aimed at both fusion signaling disruption and immune signal targeting.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365047,1790785546,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","FUTURE ONCOLOGY  \n2025, VOL. 21, NO. 10, 1249–1260  \n[https://doi.org/10.1080/14796694.2025.2477974](https://doi.org/10.1080/14796694.2025.2477974)  \n| REVIEW\u003Cbr>\u003Cbr>Clinical characterization and therapeutic targeting of fusion genes in oncology\u003Cbr>Susan Moranda, Lauren Ragerb, Daniel Craigb, Alexander Nemunaitisc, Khalil Choucaird, Donald Raoe, Laura Stanberyc,e, Richard C. Phinneyc,f, Adam Waltere,g, Maurizio Ghisolih and John Nemunaitis c,e,f\u003Cbr>aDepartment of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA; bDepartment of Medicine, University of Toledo College of Medicine, Toledo, OH, USA; cTaylor Cancer Research Center, Maumee, OH, USA; dDepartment of Hematology/Oncology, Barbara Karmanos Cancer Institute,Wayne State University, Detroit, MI, USA; eMedical Affairs, Gradalis Inc, Dallas, TX, USA; fDepartment of Hematology/Oncology, Toledo Clinic Cancer Center, Maumee, OH, USA; gDepartment of Gynecologic Oncology, Promedica Health System, Toledo, OH, USA; hDepartment of Pediatric Hematology/Oncology, Texas Oncology, P.A, Dallas, TX, USA |  |  |\n| --- | --- | --- |\n| \u003Cbr>ABSTRACT\u003Cbr>Gene fusions represent important oncogenic driver mutations resulting in aberrant cellular signaling. In up to 17% of all solid tumors at least one gene fusion can be identified. Precision therapy targeting fusion gene signaling has demonstrated effective clinical benefit. Advancements in clinically relevant next-generation sequencing and bioinformatic techniques have enabled expansion of therapeutic opportunity to subpopulations of patients with fusion gene expression. Clinically, tyrosine inhibitors have shown efficacy in treating fusion gene expressing cancers. Fusion genes are also clonal mutations, meaning it is a personal cancer target involving all cancer cells of that patient, not just a subpopulation of cancer cells within the cancer mass. Thus, both fusion signal disruption and immune signal targeting are effective therapeutic directions. This review discusses fusion gene targeting, therapeutic resistance, and molecular biomarkers.\u003Cbr>PLAIN LANGUAGE SUMMARY\u003Cbr>Genes are a segment of DNA that encode the instructions for proteins within every cell. Mutations occur when there is a change in the gene sequence. One type of mutations are gene fusions, where two genes combine and become fused together. When this happens between genes that effect normal cell functions, the cells can become cancerous. In up to 17% of all solid tumors, at least one gene fusion can be identified. Precision therapy, which can target a patient's specific cancer and gene fusion, has demonstrated effective clinical benefit. Opportunities for precision therapy have increased due to scientific advancements that allow us to sequence DNA and analyze it quickly. Current treatment for cancer with known gene fusions includes tyrosine kinase inhibitors. Fusion genes are also clonal mutations, meaning it is a personal cancer target involving all cancer cells of that patient, not just a subpopulation of cancer cells within the cancer mass. This review discusses fusion genes and ways to target these cancer signals. |  | ARTICLE HISTORY\u003Cbr>Received 15 October 2024 Accepted 7 March 2025\u003Cbr>KEYWORDS\u003Cbr>Fusion gene; liquid biopsy; clonal neoantigen; clonal mutation; solid tumor |\n| 1. Introduction\u003Cbr>Fusion genes reflect the rare but highly complex instability of genome infrastructure, resulting in random events of DNA breakage and fusion. While some alterations occur in noncoding areas (passenger mutations) with no functional consequences, other fusions involve disruptions in tumorigenesisrelated to the processing of apoptotic response, DNA damage, cell proliferation, survival, and spread. Advances in molecular techniques such as gene expression profiling, next-generation sequencing (including RNA sequencing), and bioinformatics“omics” analyses have allowed for the detection of complex fusions amenable to therapeutic interventions and for the purpose of diag","cbCaidlRztwKgYFm","https://ap.wps.com/l/cbCaidlRztwKgYFm","pdf",1425742,12,"English","# Abstract\n# Plain Language Summary\n# Introduction\n## Mechanisms of fusion gene formation and oncogenic driver roles\n# Constitutive kinase activation from fusion events\n# Clinical implications for targeted therapy","[{\"question\":\"What are fusion genes and why are they important in oncology?\",\"answer\":\"Fusion genes are oncogenic driver mutations that produce aberrant cellular signaling. They can be identified in a substantial fraction of solid tumors and contribute to cancer development and progression.\"},{\"question\":\"How have next-generation sequencing and bioinformatics expanded fusion-gene therapies?\",\"answer\":\"Advances in clinically relevant next-generation sequencing and bioinformatic analyses enable detection of fusion gene expression and broaden therapeutic opportunities for different patient subpopulations.\"},{\"question\":\"Why are fusion genes considered clonal mutations and how does that affect treatment?\",\"answer\":\"Fusion genes are clonal mutations, serving as a personal cancer target across essentially all cancer cells in a patient’s tumor mass. This supports therapeutic strategies aimed at both fusion signaling disruption and immune signal targeting.\"}]","Clinical characterization and therapeutic targeting of fusion genes in oncology | PDF",1790159881,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba5b63943a81fde7c31d06283969e1fc.webp",983,1280,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd01efbeecf33a2b79f8eac84036019f.webp",982,1278,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88019645388dc1eef7855ea0baa39373.webp",981,1277,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05487535aa385ca1b68d4fa1ef58acce.webp",980,1276]